Syfovre vs Tyrvaya
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Syfovre | US Tyrvaya | |
|---|---|---|
| Generic name | pegcetacoplan | varenicline nasal spray |
| Drug class | Complement C3 Inhibitor | Nicotinic Acetylcholine Receptor Agonist (Nasal) |
| Treats | Geographic atrophy (advanced dry AMD) | Dry eye disease |
| Category | Eye Health | Eye Health |
| Manufacturer | Apellis Pharmaceuticals | Viatris |
| Year approved | 2023 | 2021 |
| FDA warning | Moderate warnings | No boxed warning |
| Est. TV ad spend | — | — |
| Common side effects | Eye discomfort, Floaters, Bleeding in the eye, Increased eye pressure | Sneezing, Cough, Throat irritation, Nose irritation |
Frequently asked questions
Is Syfovre or Tyrvaya better?
Neither is universally "better." Syfovre (pegcetacoplan) and Tyrvaya (varenicline nasal spray) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Syfovre and Tyrvaya?
Syfovre is a Complement C3 Inhibitor made by Apellis Pharmaceuticals, while Tyrvaya is a Nicotinic Acetylcholine Receptor Agonist (Nasal) made by Viatris. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Syfovre has the larger estimated TV advertising budget of the two.